Gadice

Gadice is a London-based biotechnology company dedicated to the development of next-generation gamma delta (γδ) T cell engagers for the treatment of solid tumors. Launched in early 2025 by the founding team of GammaDelta Therapeutics and Adaptate Biotherapeutics, the company builds upon extensive expertise in γδ T cell biology and antibody engineering. Gadice's proprietary platform focuses on creating bispecific antibodies that selectively activate γδ T cells within the tumor microenvironment, potentially offering superior efficacy and safety compared to conventional αβ T cell-targeting therapies. The company is supported by a £35 million Series A investment from leading venture capital firms, including Abingworth, M Ventures, and Takeda Ventures. Gadice aims to transform the oncology landscape by providing potent, off-the-shelf immunotherapies for patients with hard-to-treat cancers.